ArticleBiomarker research2021

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.

Yutaro Kaneko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.